Lenz Therapeutics (LENZ)CFO bought ~$64K
Daniel R. Chevallard, CFO at Lenz Therapeutics, bought ~$64K of Lenz Therapeutics shares.
- ~$64K
- Approx. value · 7,500 sh @ $8.57
- 13K
- Holds after · shares reported
- Traded
- Mar 27, 2026
- Filed
- Mar 30, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Mar 24, 2026Company filing · Form 8-K · ResultsReported its results
- Mar 27, 2026 · this disclosureInsider · 3 insiders in a week, 2nd time since 2021CFO purchased ~$64K of LENZ shares in the open market
What came next
- Mar 27, 2026Insider · 2 peopleInsiders: 2 purchases (~$301K)
- May 11, 2026Company filing · Form 8-K · ResultsReported its results
- Jun 30, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On June 30, 2026, Zach Scheiner notified LENZ Therapeutics, Inc. a Delaware corporation (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”) and from all committees of the Board on which he served, effective immediately.”
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Lenz Therapeutics
OQRO holds no insider, Congress, fund or contract record for Lenz Therapeutics dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its LENZ page.
Other recent filings by Daniel R. Chevallard, Chief Financial Officer
The full history of Daniel R. Chevallard, Chief Financial Officer is on the profile page.
How this filing works
Other disclosures at Lenz Therapeutics
- SEC Form 4Mar 30, 2026
- SEC Form 4Mar 30, 2026
- SEC Form 13F-HRFeb 17, 2026
- SEC Form 13F-HRFeb 17, 2026
- SEC Form 4Nov 20, 2025
- SEC Form 4Nov 20, 2025
Everything OQRO holds on this company is on its LENZ page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data